Gilead Reports Strong Q2 2026 Growth Amid Heavy Acquisition Costs — Gilead Sciences, Inc.

Event summary

Gilead's Q2 2026 revenues increased 10% YoY to $7.8 billion, driven by HIV portfolio and Trodelvy sales.
Diluted loss per share was $(8.45) due to $9.08 per share impact from acquired IPR&D expenses related to recent acquisitions.
HIV product sales increased 12% YoY to $5.7 billion, with Biktarvy sales up 7% to $3.8 billion.
Gilead completed acquisitions of Tubulis for $3.15 billion and Ouro Medicines for $1.675 billion in Q2 2026.

The big picture

Gilead's Q2 2026 results highlight the company's strategic focus on expanding its HIV and oncology portfolios through acquisitions and clinical advancements. The significant IPR&D expenses underscore the high cost of innovation in the biopharmaceutical sector, while strong product sales demonstrate the resilience of Gilead's core business. The company's ability to navigate regulatory hurdles and competitive dynamics will be key to maintaining its growth trajectory.

What we're watching

Integration Challenges: The pace at which Gilead can integrate its recent acquisitions and realize synergies will be critical to future growth.
Regulatory Approvals: How the FDA's approval of Trodelvy for new indications and other pipeline products will impact revenue streams.
Market Competition: Whether Gilead can sustain its market share in HIV treatments amid competitive pressures and pricing reforms.